A large body of literature suggests that bone metabolism is susceptible to the ill effects of reactive species that accumulate in the body and cause cellular dysfunction. One of the body's front lines in defense against such damage is the transcription factor, Nrf2. This transcription factor regulates a plethora of antioxidant and cellular defense pathways to protect cells from such damage. Despite the breadth of knowledge of both the function of Nrf2 and the effects of reactive species in bone metabolism, the direct role of Nrf2 in skeletal biology has yet to be thoroughly examined. Thus, in the current study, we have examined the role of Nrf2 in postnatal bone metabolism in mice. Mice lacking Nrf2 (Nrf2
INTRODUCTION
Postnatal bone growth in mammals involves the concerted action of three principal cell types: osteoblasts, osteoclasts and osteocytes. 1 Osteoblasts, derived of a mesenchymal origin, produce the organic bone matrix that is composed largely of type I collagen and facilitate its mineralization. 2 During this process, a subset of osteoblasts become entombed in the newly produced matrix and further differentiates into osteocytes. These osteocytes form a vast interconnected network of cells within the bone that continue to promote mineralization of the newly deposited matrix, as well as perform additional functions of mechanosensing, regulating local bone turnover and participating in endocrine signaling. [3] [4] Osteoclasts, derived of hematopoietic origin, are responsible for the resorption of mineralized bone matrix to facilitate bone remodeling and maintain serum calcium levels. 5 A considerable body of literature exists that implicates the accumulation of reactive oxygen species (ROS) and other free radicals as a major contributor to the functional decline observed in numerous tissues and cellular processes [6] [7] and it is highly unlikely bone would be an exception. Indeed, recent studies in both animals and humans 8 suggest roles-both physiological and pathological-for ROS in the regulation of bone mass. ROS are formed predominantly in mitochondria as electrons escape the electron transport chain during the aerobic metabolism of glucose and fats to generate ATP. 9 Until recently, these ROS were believed to be an unavoidable, deleterious by-product of cellular metabolism in an oxygen-rich environment. However, extensive data are emerging that indicates that ROS are purposely produced by cells to trigger physiological signaling cascades (ERK, p38, JNK, PI3K/Akt, AP-1, p53, Wnt/b-catenin), as well as activate or modify the activity of tyrosine phosphatases, proteases, chaperones and transcription factors (NF-kB, glucocorticoid receptor, estrogen receptor, HIF-1a, etc.). 10 In this regard, ROS and other free radicals seem to behave with a split personality in the cell, reminiscent of Dr Jekyll and Mr Hyde. At low levels, ROS contribute positively to cellular processes, often acting as mitogens and stimulating differentiation. At high levels, we observe the cellular damage (protein adducts, lipid oxidation, DNA damage, etc.) for which ROS and other radical species first gained notoriety. Thus, cells contain elaborate antioxidant and detoxifying enzyme systems that are responsible for precisely regulating the levels of free radical species (glutathione peroxidase, GSH, glutathione S-transferase, superoxide dismutase, NADPH quinone oxidoreductase-1, heme oxygenase-1, ferritin H, etc.).
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While some of these antioxidant and detoxification pathways function basally in cells, many more are upregulated in response to endogenous or exogenous stressors. One such 'master regulatory' antioxidant response pathway is controlled by the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2).
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Nrf2 is a prolific transcription factor, activated in response to oxidative stress caused by wide variety of environmental or endogenous stressors. In an unstressed condition, Nrf2 is sequestered in the cytoplasm by Kelch ECH associating protein 1 (Keap1) and targeted for proteosomal degradation via cullin 3 ubiqutin ligase. Keap1 serves as the primary sensor of various free radical stresses, and upon experiencing a stress signal, Keap1 undergoes a conformational change resulting in loss of Keap1-cullin 3 ligase activity and stabilization of Nrf2. Free to translocate to the nucleus, Nrf2 regulates the transcription of broad range of genes (antioxidant enzymes, glutathione homeostasis, proteasome pathway, detoxification enzymes, etc.) whose promoters contain an antioxidant response element. 12 Our studies and others have shown that in mice, disruption of Nrf2 significantly impairs the induction of these downstream cellular defense pathways and exaggerates the effects of oxidative stress, nitrosative stress, inflammation and endoplasmic reticulum stress after exposure to environmental agents, such as cigarette smoke, 13-17 bacteria [18] [19] [20] or viruses. [21] [22] Conversely, enhancing the Nrf2 signaling pathway by genetic disruption of its inhibitor partner, Keap1, increases antioxidant defenses and diminishes tissue injury caused by smoking. 19, 23 This pathway is highly conserved, 24 and we have recently demonstrated that a defect in Nrf2 signaling pathways occurs in COPD patients that renders them susceptible to pathological drivers of COPD such as oxidative stress and inflammation. [14] [15] 25 Additionally, human DNA polymorphisms leading to reduced Nrf2 abundance [26] [27] have been associated with skin vitiligo, 28 chronic gastritis, 29 peptic ulcer, 30 ulcerative colitis 31 and adult respiratory distress syndrome. 27 Despite ample evidence implicating oxidative stress in age-related bone loss in humans, [32] [33] [34] [35] [36] [37] [38] [39] and the prominent role of Nrf2 in responding to oxidative stress in other tissues, the involvement of Nrf2 in skeletal maintenance has not been thoroughly examined. In this study, we have examined the effect of loss of Nrf2 throughout the postnatal skeletal development of mice. We have found that Nrf2 is critical for normal postnatal bone development, as mice lacking Nrf2 demonstrated significantly impaired bone acquisition and reduced bone volume. These changes appear to be primarily due to defects in osteoblastogenesis that result from increased oxidative stress in the absence of Nrf2. collagenase type I (Worthington, Lakewood, NJ, USA) solution. Calvaria were digested in 10 mL of digestion solution for 15 min at 37 6 C with constant agitation. The digestion solution was collected, and digestion was repeated with fresh digestion solution an additional four times. Digestions 3-5 (containing the osteoblasts) were pooled together, centrifuged, washed with a-MEM containing 10% FBS, 1% pen/strep and plated overnight at 37 6 C in a humidified Nrf2 in bone JH Kim et al 2 incubator supplied with 5% CO 2 . For differentiation assays, osteoblasts were grown to confluence and then switched to differentiation media supplemented with b-glycerophosphate and ascorbic acid for 14 days prior to alkaline phosphatase (ALP) staining or 21 days prior to alizarin red S (ARS) staining by standard methods. ALP and ARS staining was quantified by image density analysis of plate images using ImageJ software (NIH, Bethesda, MD, USA).
MATERIALS AND METHODS

Materials
Osteoblast proliferation assays Osteoblasts were plated in six-well plates at low cell density Colony-forming unit (CFU) assays CFU-osteoblast (CFU-OB) assay using stromal flushes were performed on femurs and tibiae of 8-week-old female control and Nrf2 2/2 mice, and these cells were plated at low density in triplicate. Non-adherent cells were removed the after four days, and the adherent stromal population was allowed to grow in osteogenic differentiation media for 18 days. The number of osteoblast colonies was assessed by both ALP and ARS staining and followed by methylene blue staining to assess total number of colonies. and 24 weeks of age ( Figure 2 and Table 1 ). At 3 weeks of age, osteoblast numbers were 12-fold lower in Nrf2
Osteoclastogenesis assays
mice as compared to control mice (Figure 2a) . However, the osteoblast number per bone length rapidly compensated and was similar between the genotypes by 6 weeks of age, remaining so throughout all remaining time points. There were no significant differences in osteoclast number per bone length or resorption-related parameters between control and Nrf2 2/2 mice at any of the indicated ages (Figure 2b ), suggesting that an osteoblast defect was primarily responsible for the reduced bone phenotype observed in vivo. While there were some transient (Figure 3a) . We also examined primary osteoblast differentiation in control and Nrf2 2/2 primary calvarial osteoblasts, given the transient decrease in formation-related histomorphometric parameters observed in 8-week-old Nrf2 2/2 mice in vivo. Again, in contrast to our expectation, there were no significant differences in ALP or ARS staining following 14 or 21 days of culture in osteogenic media, respectively (Figure 3b and 3c) . 
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Deletion of Nrf2 impairs colony-forming capacity of bone marrow stromal cells Given that we did not observe any functional deficit in osteoblasts in vitro, we next sought to determine whether the reduction in osteoblast numbers observed in vivo might have been due to impairment of bone marrow stromal cell (BMSC) function. We have previously reported that deletion of Nrf2 decreases antioxidant defenses and survival signals, which attenuate the proliferative capacity of hematopoietic stem progenitor cells in vitro and in vivo. 44 In accord 
Nrf2 in bone JH Kim et al 6
supplementation restored the number of colonies formed in Nrf2 2/2 BMSCs to levels equal to, or greater in the case of CFU-OB (ALP), than that of control BMSCs (Figure 4b-4e) . Taken together, these data suggest that poor postnatal bone acquisition in Nrf2 2/2 mice might result from a failure in the proliferative/survival capacity of the osteoprogenitor population, which results in the low osteoblast numbers observed early in the life of Nrf2 2/2 mice.
Osteoclastogenesis is dramatically enhanced in the absence of Nrf2 in vitro, but not in vivo Our data, so far, have indicated that the reduced postnatal bone acquisition observed in Nrf2 2/2 mice is primarily the result of dramatically reduced osteoblast numbers in early life, which likely results from impaired BMSC proliferation or survival and a subsequent lack of osteoprogenitors. However, our previous studies indicated that loss of Nrf2 has deleterious effects on hematopoietic populations as well, from which osteoclasts are derived. Thus, our final question was whether loss of Nrf2 had any impact on osteoclastogenesis. Quite to our surprise since Nrf2 Thus, while Nrf2 appears to be inhibitory for osteoclastogenesis in vitro, there appear to be compensatory mechanisms in vivo that nullify these effects.
DISCUSSION
The deleterious effects of reactive species in bone have been extensively studied. Likewise, the function of the master regulatory transcription factor, Nrf2, has been thoroughly detailed in response to various cellular stresses. However, the role of Nrf2, itself, in bone metabolism has not been adequately examined to date. In the present studies, we examined the effect of loss of Nrf2 on bone metabolism throughout postnatal life in mice. Interestingly, loss of Nrf2 resulted in a failure of normal bone acquisition in mice, with the deficit appearing most severe at a young age and correcting by adulthood. This is in contrast to the traditional view of how reactive species impact bone metabolism-slowly accumulating throughout life and ultimately leading to cellular dysfunction 6 -and may ultimately highlight physiological roles of reactive species that are critical in early life, particularly in progenitor populations. Histomorphometric analysis suggested that the poor acquisition of bone mass in Nrf2 2/2 mice was the result of dramatically reduced osteoblast numbers early in life (3 weeks of age). While osteoblast numbers recovered during pubertal growth and remained comparable to BMSCs to levels comparable to control BMSCs. We believe this to be the cause of the early defect in osteoblast number observed in Nrf2 2/2 mice, as we were unable to detect any primary defect in osteoblast function. It is likely that, in the whole animal, additional mechanisms to activate antioxidant pathways independent of Nrf2 signaling, such as FoxO, 46 could compensate for the loss of Nrf2 and are responsible for the recovery of osteoblast numbers observed during pubertal growth. This hypothesis will be tested in future studies, in which we will attempt to rescue this early phenotype through administration of NAC to young animals. Interestingly, despite any evidence for osteoclastic involvement in the phenotype observed in vivo, this population of cells is strikingly affected by loss of Nrf2 in vitro. Similar results have also been observed in a recent report by Park et al., 47 in which they also observed no osteoclastic phenotype in Nrf2 2/2 mice, but dramatic increases in osteoclastogenesis in vitro, owing to Nrf2 inhibiting activation of NF-kB and induction of c-fos and NFATc1. 47 Also similar to the findings of Park and colleagues, we observed a reduction in the RANKL/OPG ratio in Nrf2 2/2 mice, which may explain the discrepancy between this osteoclastic phenotype in vitro and the lack of any osteoclast disturbance in vivo. Finally, despite many similarities in our findings and those of the recent report by Park and colleagues, they reached the conclusion that Nrf2 is solely an inhibitor of bone acquisition and showed increased bone volume in
Nrf2
2/2 mice by micro-CT analysis at 9 weeks of age. This is, obviously, in stark contrast to our present findings, although we are inclined to believe that both pieces of work are accurate. First, we used female animals for the experiments described, whereas the sex of animals used in their studies was not stated. It is possible that there may be sexual dimorphism in the phenotype. Moreover, Park and colleagues examined only a single time point-9 weeks of age. In our examination of bone volume in the Nrf2 2/2 mice, we observed an initial failure in bone acquisition at 3 weeks, which then caught up to control animals by 12 weeks of age. We observed 45%, 30% and 20% reductions in bone volume fraction (BV/TV) in Nrf2 2/2 mice compared to controls at 3, 6 and 8 weeks of age, respectively (Figure 1a and 1b), so it is entirely possible that in the time between 8 and 12 weeks of age, the Nrf2 2/2 mice may overshoot control animals in attaining their own peak bone mass. Consistent with our current findings in global Nrf2
mice, previous studies have demonstrated that osteoblast-targeted deletion of family member Nrf1 resulted in reduced trabecular bone volume. 48 Differences in the diet or genetic background (i.e., variable compensatory responses from Nrf family members Nrf1 and Nrf3) of animals could also contribute to the contrasting in vivo results with the Park et al.'s study. Regardless, both studies indicate Nrf2 is a key player in skeletal development, which is worthy of future study and may ultimately provide additional therapeutic targets for age-related bone loss.
